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We investigate over a 12-year period the association between regional cerebral blood flow (CBF) and
cardiovascular risk factors in a prospective cohort of healthy older adults (81.96  3.82 year-old) from the
Cognitive REServe and Clinical ENDOphenotype (CRESCENDO) study. Cardiovascular risk factors were
measured over 12 years, and gray matter CBF was measured at the end of the study from high-resolution
magnetic resonance imaging using arterial spin labeling. The association between cardiovascular risk
factors, their long-term change, and CBF was assessed using multivariate linear regression models.
Women were observed to have higher CBF than men (p < 0.05). Increased mean arterial pressure (MAP)
over the 12-year period was correlated with a low cerebral blood flow (p < 0.05, R2 ¼ 0.21), whereas no
association was detected between CBF and MAP at the time of imaging. High levels of glycemia tended to
be associated with low cerebral blood flow values (p < 0.05). Age, alcohol consumption, smoking status,
body mass index, history of cardiovascular disease, and hypertension were not associated with CBF. Our
main result suggests that change in MAP is the most significant predictor of future CBF in older adults.
 2016 Elsevier Inc. All rights reserved.1. Introduction
In older adults subjects to cardiovascular risk, low cerebral blood
flow (CBF) has been associated both with age-related neurode-
generative diseases such as vascular dementia and Alzheimer’sadiology, University Hospital
in Fliche, 34295 Montpellier
67 33 0674.
dun).
ll rights reserved.disease (Schuff et al., 2009; Yoshikawa et al., 2003), and also
increased risk of all-cause mortality (Sabayan et al., 2013). This
would suggest a chain of events in which cumulative exposure to
cardiovascular risk factors over time leads to CBF changes, which in
turn increase vulnerability to adverse health outcomes, including
not only cardiovascular diseases (CVDs) per se but also neurode-
generative ones, and decreased life expectancy due to all causes. As
cardiovascular risk factors are largely reversible, this may constitute
an effective way to reduce pathogenic changes associated with
abnormal CBF levels.
J. Deverdun et al. / Neurobiology of Aging 46 (2016) 49e5750In this context, it is important to determine which cardiovas-
cular risk factors carry the highest risk of CBF modification. Arterial
spin labeling provides a quantitative and noninvasivemeasurement
of gray matter (GM) CBF (van Gelderen et al., 2008) yielding similar
results to positron emission tomography (Arbeláez et al., 2013).
The present study aimed to assess in a cohort of healthy older
adults the influence of cardiovascular risk factors, as evaluated
longitudinally over a 12-year period, on global measures of CBF
assessed at 12 years from baseline.
2. Materials and methods
2.1. Population
The data were derived from the prospective Montpellier-Three-
City study (3C Study Group, 2003) in which healthy older adults
volunteers (age >65-year old), underwent a standardized evalua-
tion with a face to face interview, and a clinical examination at
baseline (1999e2001). The ancillary Cognitive REServe and Clinical
ENDOphenotype (CRESCENDO) study initiated by the National
Institute of Health and Medical research and carried out in the
Human Functional Imaging Institute (I2FH, Montpellier University
Hospital, France) was selected specifically to identify magnetic
resonance imaging (MRI) biomarkers of cognitive reserve.
Volunteers selected to participate in the CRESCENDO study were
free of dementia. Baseline diagnosis of dementia was based on a
3-step procedure (3C StudyGroup, 2003). First, trained psychologists
administered a battery of neuropsychological tests (Akbaraly et al.,
2009). Second, all the participants were examined by a neurologist.
Finally, an independent committee of neurologists reviewed all po-
tential prevalent and incident cases of dementia to obtain a
consensuson itsdiagnosis andetiologyaccording to thecriteria of the
Diagnostic and Statistical Manual ofMental Disorders, fourth edition
(American Psychiatric Association, 1994). Similar procedures were
performed at the 5 next follow-ups for incident dementia screening.
CasesofADwere classifiedaccording to theNINCDeADRDA(National
Institute of Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders Association) and
cases of mixed and/or vascular dementia according to the
NINCDSeAIREN (National Institute of Neurological Disorders and
Stroke and Association Internationale pour la Recherché et
l’Enseignement en Neurosciences) criteria (Akbaraly et al., 2009). At
12-year follow-up, participants free of dementia were invited to
undergo a high-resolution MRI and complementary clinical exami-
nationas part of theCRESCENDOstudy (n¼380, 67.3%women,mean
age of 81.96 3.82-year old). The studyprotocolwas approvedby the
ethics committee of the University-Hospital of Bicêtre and written
informed consent was obtained from each participant.
2.2. Assessment of cardiovascular risk factors
Health behavior was assessed at baseline and consisted of
smoking status (non/former/current smoker) and alcohol con-
sumption (null/moderate/important) (Akbaraly et al., 2011; Carriere
et al., 2014). Health status was ascertained at 12-year of follow-up
by self-reported history of CVD (Akbaraly et al., 2011). Anteced-
ents to be reported included stroke, angina pectoris, myocardial
infarction, coronary surgery, coronary angioplasty, and arterial
surgery of the legs for arteritis (Akbaraly et al., 2011; Carriere et al.,
2014). Note that no participant reported antecedents of stroke.
Bothatbaselineandat10yearsof follow-up, informationonweight,
height, and use of medication were collected; fasting blood glucose,
total-, high density lipoprotein-, low density lipoprotein-cholesterol,
and triglycerides were measured as described in the study by
Akbaraly et al. (2011). Based on these data, participants withdyslipidemia were defined as those with total cholesterol above
6.2 mmol/L or those using lipid-lowering drugs (Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) 2001). Change in cholesterol
(DChol), body mass index (DBMI), and glycemia (DGlyc) was assessed
using the 2 available points (2 and 10 years) usingDFactor¼ (Factor0
Factor10)/(Factor0).
At the baseline clinical examination, 2 separate blood pressure
measures in a seated position were performed in all participants,
the first one before and the second one during the interview, using
a digital electronic tensiometer (OMRON M4), and the mean of the
2 was computed. In the few cases where the 2 measures were not
available, the single measure has been considered.
During follow-up, systolic and diastolic blood pressure were
measured again at 2, 4, 7, 10, and 12 years. Mean arterial pressure
(MAP)was retrieved from the systolic and diastolic arterial pressure
using the formula: MAP ¼ ([2  Pdiastolic]þPsystolic)/3. For cross-
sectional analysis, MAP at 12 years was used. Pulse pressure was
also retrieved using the difference between systolic and diastolic
pressure. Change inMAP (DMAP), systolic pressure (DSBP), diastolic
pressure (DDBP), and pulse pressure (DPP) were calculated as the
linear fit slope of the variables across all available time points.
Hypertension was defined from systolic and diastolic blood
pressure, respectively, above 140 and 90 mmHg or from the use of
antihypertensive drugs. Please note that each time we do not refer
to an evolution, we will refer to the last available time point, which
is the 10 years of follow up for biological data and 12 years for the
others parameters.
2.3. MRI acquisition
Neuroimaging data were collected on a 3T magnet (Skyra,
Siemens, Germany) with a 32 channels head coil. Structural
images (3DT1) were acquired with the parameters: field of
view¼ 25  25 cm, echo time (TE) ¼ 2.5 ms, repetition time (TR) ¼
1690 ms, flip angle ¼ 9, voxel size ¼ 0.98  0.98  1 mm3, 176
slices. Fluid-Attenuated Inversion Recovery (FLAIR) image was ac-
quired to estimate white matter (WM) lesions with the following
parameters: field of view¼ 22 22 cm, TE¼ 111ms, TR¼ 7000ms,
flip angle ¼ 150, voxel size ¼ 0.86  0.86  3 mm3, 39 slices. CBF
data were acquired using a 2D-pulsed arterial spin labeling
sequence, PICORE-Q2TIPS (Luh et al., 1999), TI1/TI2/TR/TE ¼ 700/
2000/3000/20 ms, 52 repetitions, 16 slices (1.5 mm gap), voxel
size ¼ 3.44  3.44  6 mm3.
2.4. FLAIR and T1 processing
Volumetric T1 and FLAIR images were checked for major signal
abnormalities, using Myrian (Myrian Expert VL, Intrasense, France).
The preprocessing was performed using a customMATLAB code
(the MathWorks, Natick, MA, USA) and SPM8 (Statistical Para-
metric Mapping; the Wellcome Trust Center for Neuroimaging,
UK), and all images were reoriented according to the anterior
commissure.
The frequency of WM hyperintensities increases with advancing
age (Awad et al., 1986), it was therefore important to take them into
account in our processing. Owing to their intensity on T1, they may
be erroneously segmented as GM. Thus, WM hyperintensities were
segmented using the SPM Lesion Segmentation Tool toolbox
(Schmidt et al., 2012). Using the same tool, areas identified as WM
hyperintensities on FLAIR and responsible of hypointense lesions
on T1 were filled by the mean global WM intensity of the subject.
Standard SPM segmentationwas then performed onT1 to extract
GM, WM, and cerebrospinal fluid posterior probability. Finally, seg-
mentations were coregistered to mean arterial spin labelling image.
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Arterial spin labeling images were realigned according to the
baseline magnetization M0 image acquired with a long repetition
time.
Participants with major movements or artifacts were removed.
The label images were then subtracted pairwise from the time
matched control images using surround subtraction, to produce
perfusion-weighted images. Finally, averaging is performed to get a
single perfusion-weighted image.
To ensure a correct estimation of the CBF, Asllani’s et al. partial
volume effects (PVE) correction (Asllani et al, 2008) was applied in
native space, using a 7  7  1 voxel regression kernel.
CBF computation was performed using a 1 compartment model







whereDM is the signal intensitymean difference between label and
control images, l the blood and/or tissuewater partition coefficient,
T1a the longitudinal relaxation time of blood, a the inversion effi-
ciency, and M0 the blood magnetization.
We chose to use the estimation of GM DM and M0 given by the
PVE correction to compute the GM CBF. The blood magnetization
(M0) was estimated using the local tissue method (Cavus¸oglu et al.,
2009).
The parameters used for the quantification were labeling
efficiency¼ 0.95; longitudinal relaxation, T1a ¼1664ms; and as we
focused on GM, lGM ¼ 0.98.2.6. Image quality control
After realignment, participants presenting major movements or
missing images were removed from analysis (n ¼ 17). Then, before
averaging, perfusion-weighted images were labeled as unusable if
containing more than 50% of negative values. Participants with
more than 20% of unusable perfusion-weighted images were
excluded from subsequent analysis (n ¼ 224; Fig. 1). For remaining
participants, mean difference was obtained by averaging the
remaining perfusion images.
After quantification, we further excluded from analysis the
participants for whom the labeling was clearly inhomogeneous, in
the absence of signal abnormalities on FLAIR sequences that could
explain perfusion heterogeneity (n ¼ 16; Fig. 1). Eventually, from
the 380 participants originally included in the CRESCENDO project,
104 only had data suitable for CBF estimation.
From a methodological point of view, this large number of
excluded participants may question the capacity of arterial spin
labeling (ASL) to provide valid CBF quantification in older adults.
We claim (see Section 4 Discussion) that this is the consequence of
the selection of a single inversion time for all participants.
To validate this hypothesis, we performed test acquisitions on 6
healthy participants selected in our institute (mean age 24.5  2
year-old) assuming that the effects of incorrect inversion time on
young and older adults are the same regarding unusable perfusion-
weighted images. Multiple arterial spin labeling acquisitions were
performed using the same parameters used in our cohort but
with varying inversion time (1300, 1400, 1500, 1600, 1700, 1800,
1900, and 2000 ms). To estimate the bolus arrival time, an addi-
tional 3D-GRASE arterial spin labeling acquisition (Günther et al.,
2005) was performed using 16 inversion time (ranging from
480 to 4000 ms) with the parameters bolus duration 700 ms,TR ¼ 3000 ms, TE ¼ 20 ms, parallel imaging factor ¼ 2, 24 slices,
voxel size ¼ 3.4  3.4  4 mm3. Bolus arrival time maps were
generated online using the Siemens automatic pipeline. A radiolo-
gist identified the real optimal inversion time by drawing circular
regions of interest in GM of different vascular territories on bolus
arrival time map for each participant.2.7. Data extraction
Mean GM CBF was retrieved from PVE-corrected CBF map by
applying the GM posterior probability (threshold ¼ 0.8) obtained
from T1 segmentation.2.8. Statistical analysis
Skewed variables (CBF) were log-transformed to normalize their
distribution before statistical analyses.
A first set of analyses were conducted to examine the CBF dif-
ferences according to sex and age. Mean comparisons using Student
t-test were performed to compare global and regional CBF mea-
sures between men and women.
Correlation analyses (Pearson’s correlation coefficient) have
been performed to examine the association between age and CBF
measures.
To assess the association between cardiovascular risk factors
assessed at baseline, or their change over the follow-up and CBF
measures, linear regression models were performed adjusted for
sex and age.
The p-values below 0.0022 (0.05 corrected for multiple com-
parisons using a Bonferroni’s correction) were considered to be
statistically significant. Analyses were performed using R software,
version 3.0.2.3. Results
The mean CBF value across the entire GM volume was 45.2
 10.6 mL/100 g/min. Detailed results of the statistical analysis
performed are presented in Table 1. Note that we also performed
regional analysis which are reported as Supplementary materials;
they do not present further significant results.3.1. Sex and age
Women showed significant higher CBF levels thanmen (women:
47.2  10.8 mL/100 g/min and men: 41.3  9.4 ml/100 g/min; see
details in Electronic Supplementary Material). Age was not corre-
lated to CBF (Table 1).3.2. Health behaviors
No association was found between smoking status and alcohol
consumption assessed at baseline and CBF levels assessed 12 years
later.3.3. Diabetic status and blood glucose
We did not find significant association between type 2 diabetes
(13 patients) and CBF. However a trend of a reduced CBF with high
levels of fasting blood glucose was found (p ¼ 0.05, R2 ¼ 0.10).
Similarly, the analysis of longitudinal data shows a trend to a
reduced CBF with increasing glycemia (p ¼ 0.04, R2 ¼ 0.10).
Fig. 1. Flow charts showing of the participants’ selection. Participants who did not fit the requirements (missing data, major artifacts, and so forth) were excluded. Perfusion-
weighted images were checked and labeled as unusable when they contained more than 50% of obvious artifacts such as negative values. Participants with more than 20% of
perfusion-weighted images identified as unusable were excluded from subsequent analysis (n ¼ 224). An example of the inhomogeneity issue is display, on the left (A), the CBF map,
and on the right the corresponding FLAIR image (B). Although there is a clear signal difference between left and right hemisphere on CBF map, no evidence of pathology is visible on
FLAIR. Abbreviations: CBF, cerebral blood flow; CRESCENDO, Cognitive REServe and Clinical ENDOphenotype; FLAIR, fluid-attenuated inversion recovery.
J. Deverdun et al. / Neurobiology of Aging 46 (2016) 49e57523.4. Dyslipidemia status and blood lipids
Neither dyslipidemia status nor total cholesterol was associated
with CBF. Increase or decrease in cholesterol (DChol) over 10 years
was not correlated to CBF.
3.5. Body mass index
Body mass index did not exhibit any link with CBF in neither
cross-sectional nor longitudinal analysis.
3.6. Hypertension status and MAP
For hypertension, no association was observed with CBF.
No observable association between baseline or follow-up MAP
values and mean CBF was detected (Fig. 2A). The same result holds
regarding systolic, diastolic, and pulse pressure.
IncreasedMAPover12yearswasassociatedwith lowerCBFacross
the whole GM (p < 0.0022, R2 ¼ 0.21, Fig. 2B). Evolutions of systolic
anddiastolic bloodpressure exhibit the same trend, although there is
a statistical significance loss after Bonferroni’s correction (p¼ 0.004,
R2 ¼ 0.19 and p ¼ 0.01, R2 ¼ 0.09, respectively).
3.7. Self-reported CVDs
No significant trends were observed in global CBF values between
participantswhoself-reportedCVDcomparedwith thosewhodidnot.3.8. Population selection bias
Differences in characteristics between our sample and the
excluded participants (based on the CBF quantification quality
criterium) were examined and given in Table 2.
Participants retained for our analysis exhibit a significant dif-
ference compared with the whole group in term of glycemia value,
as well as its evolution (p < 0.01, Table 2).
BMI and DBMI were also found significantly different between
excluded participants and retained sample (p < 0.01).
4. Discussion
This study investigated the relationship between long-term
evolution of cardiovascular risk factors and cerebral perfusion
acquired at 1 time point, in an epidemiological cohort study of
healthy older adults. Using arterial spin labeling methods, global
GM CBF has been estimated, with values in agreement with those
observed in other reports (Brumm et al., 2010; Chen et al., 2011),
including differences according to sex.
More specifically, our findings showed that among the cardiovas-
cular risk factors, onlychange inMAPwas stronglyassociatedwithCBF.
4.1. Blood pressure
One of the major finding of this study is the association
between MAP and CBF. In coherence with recent findings
Table 1
Results of the statistical analysis of the correlation of cerebral blood flow (CBF) and
various factors
Factors p-value R2 b Standard
error
Age 0.88 NA NA NA
Sex 0.002* NA NA NA
Systolic pressure 0.53 0.06 0.0008 0.001
Evolution of systolic pressure 0.004 0.19 0.06 0.02
Diastolic pressure 0.12 0.08 0.004 0.002
Evolution of diastolic pressure 0.01 0.15 0.09 0.04
Mean arterial pressure 0.16 0.10 0.003 0.002
Evolution of mean arterial pressure 0.002* 0.21 0.1 0.03
Pulse pressure 0.83 0.06 0.0003 0.001
Evolution of pulse pressure 0.06 0.13 0.04 0.02
Hypertension 0.73 0.05 0.02 0.05
Diabetes 0.53 0.06 0.04 0.07
Glycemia 0.04 0.10 0.06 0.03
Evolution of glycemia 0.05 0.10 0.38 0.19
Dyslipidemia 0.30 0.08 0.05 0.05
Cholesterol 0.24 0.08 0.03 0.02
HDL 0.31 0.07 0.07 0.07
LDL 0.20 0.08 0.03 0.03
Triglycerides 0.09 0.09 0.07 0.04
Evolution of cholesterol 0.69 0.06 0.0005 0.001
Body mass index 0.59 0.05 0.005 0.008
Evolution of body mass index 0.47 0.06 0.23 0.32
Alcohol 0.94 0.05 0.003 0.04
Smoking 0.60 0.05 0.02 0.04
Cardiovascular disease 0.78 0.05 0.02 0.06
Age results were obtained from a Pearson correlation, a 1 tailed t-test was used for
gender, and for the others parameters, multivariate linear regression with adjust-
ment on gender and age was used. Significance is indicated by p (p-value), adjusted
R2, b, and standard error are also reported when available, p-values are bold if
inferior or equal to 0.05. Significant association on CBF after correction for multiple
comparisons (Bonferroni’s corrected p-value: 0.0022) are displayed with a star.
Key: HDL, high density lipoprotein; LDL, low density lipoprotein.
J. Deverdun et al. / Neurobiology of Aging 46 (2016) 49e57 53(Foster-Dingley et al., 2015), neither hypertension status nor MAP,
systolic, or diastolic blood pressure were associated with CBF. Only
MAP long-term evolution was associated to CBF, and not baseline
nor follow-up values. This rules out the possibility that some initial
or final health status of the participants is the source of the effect.
To maintain consistent CBF in the face of variability in MAP, the
brain adapts its vasculature through a group of mechanisms
referred to as cerebral autoregulation (Paulson et al., 1990). The
absence of association of CBF to MAP at 1 time point tends to
reveal that these mechanisms can be preserved in healthy olderFig. 2. Adjusted cerebral blood flow (CBF) according to baseline, final, and evolution of mean
for age and sex. The values of the MAP at baseline (T ¼ 0) and at the magnetic resonance im
regressions. No significant associations were found between those factors and the CBF (
significantly associated to evolution of MAP (p ¼ 0.002).adults, as was established in younger cohorts (Lipsitz et al., 2000;
Oudegeest-Sander et al., 2014; van Beek et al., 2008). Rather than
the MAP baseline value or its measurement at the 12-year follow-
up, it appears that the major factor that affects the CBF is the
12-year evolution (DMAP). Our results show that increase in MAP
(DMAP >0) is associated to lower CBF and that decreasing MAP is
correlated to higher CBF. The evolutions of systolic blood pressure,
and to a lesser extent of diastolic blood pressure, are similar to
DMAP in terms of association with CBF, although loosing signifi-
cance after Bonferroni’s correction.
It is well-known that CVDs can be associated with long-term
changes in cerebral autoregulation. Chronic hypertension is
known to shift to higher values the pressure range associated to CBF
stability (Traon et al., 2002). Older adults are moreover known to
have a lower stable CBF value than mid-age individuals.
Our results show that in healthy older subjects, long-term MAP
evolution (and not single time MAP measures) could be inversely
associated to stable CBF values. Interestingly, we observe that for
negative DMAP, CBF values are then closer to those observed in
mid-age.
Previous studies have suggested this relation between CBF and
MAP changes in older adults with blood pressure lowering therapy
(Lipsitz et al., 2005; Tryambake et al., 2013). Based on this and our
results, it is possible that observations obtained from intensive
medication (Lipsitz et al., 2005; Tryambake et al., 2013) can occur in
standard conditions (without medication) but with longer delays.
Of course, it is important to note that evolution of MAP could be
an effect of the antihypertensive drugs. Nevertheless, in our cohort,
less than a third of the participants began a treatment during the
study, and none stopped their hypertensive medication. We
investigated differences in the evolution of MAP between stable
participants (regarding the treatment) and newly treated ones, but
these groups are statistically similar (2 tailed t-test, p ¼ 0.72).
Note also that pulse pressure and its evolution were not asso-
ciated with CBF. This result was expected, as both systolic and
diastolic blood pressures have the same trend of association with
CBF (inversely associated to CBF).4.2. Sex and age
Our observed lower global CBF values in men compared with
women have been previously established in older adults (Chen
et al., 2011; Liu et al., 2011). It is therefore important to take intoarterial pressure (MAP). (A) This shows the results of the linear model after adjustments
aging time (T ¼ 12) are displayed as black crosses and blue circles with their respective
p > 0.05). The results with the evolution of MAP are displayed in (B). The CBF was
Table 2
Characteristics of study participants in the whole study and sample used
Characteristics Excluded participants Usable data p-value
Value Availability Value Availability
Sociodemographic factors
Male 134 (48.5 %) 276 34 (32.7 %) 104 0.005
Age, y 82.25 (3.97) 276 81.3 (3.3) 104 0.03
Cognitive status
MMSE 28.45 (1.61) 270 28.78 (1.35) 101 0.07
NART 22.54 (5.77) 273 22.28 (5.86) 102 0.70
Alcohol consumption
None, n (%) 34 (12.8 %) 266 13 (12.7 %) 102 0.57
Moderate, n (%) 172 (64.7 %) 266 71 (69.6 %) 102 0.57
High, n (%) 60 (22.6 %) 266 18 (17.6 %) 102 0.57
Smoking status
Nonsmoker, n (%) 164 (59.4 %) 276 70 (67.3 %) 104 0.35
Former smoker, n (%) 93 (33.7 %) 276 29 (27.8 %) 104 0.35
Current smoker, n (%) 19 (6.9 %) 276 5 (4.7%) 104 0.35
Biological data
BMI, kg/m2 24.72 (3.39) 274 23.2 (2.76) 103 <0.001
DBMI 0.002 (0.08) 265 0.02 (0.07) 103 0.008
Glycemia, mmol/L 5.46 (0.93) 236 5.17 (0.71) 90 0.007
DGlyc 0.10 (0.16) 236 0.08 (0.12) 90 <0.001
Diabetic status, n (%) 43 (18 %) 238 13 (14.1%) 92 0.39
HDL, mmol/L 1.55 (0.37) 235 1.62 (0.36) 90 0.08
LDL, mmol/L 3.40 (0.93) 235 3.46 (0.88) 90 0.6
Triglycerides, mmol/L 1.27 (0.52) 235 1.20 (0.53) 90 0.3
Total cholesterol, mmol/L 5.53 (1.08) 235 5.64 (1.04) 90 0.41
DChol 0.04 (0.2) 235 0.05 (0.19) 90 0.61
Dyslipidemia, n (%) 147 (60 %) 245 56 (53.8%) 95 0.86
Cardiovascular factors
MAP, mmHg 96.73 (11) 269 96.7 (10.9) 91 0.99
DMAP 0.03 (1.03) 209 0.23 (0.82) 71 0.05
Systolic blood pressure (SBP) 142 (17.6) 269 143.7 (18.36) 91 0.42
DSBP 0.65 (1.66) 209 1.05 (1.39) 71 0.06
Diastolic blood pressure (DBP) 74 (10.3) 269 73.4 (9.4) 91 0.55
DDBP 0.37 (0.95) 209 0.18 (0.7) 71 0.11
Pulse pressure (PP) 67.95 (15.4) 269 70.3 (16.27) 91 0.16
DPP 1.01 (1.23) 209 1.23 (1.17) 71 0.19
Hypertension, n (%) 215 (78.75 %) 273 75 (73 %) 103 0.22
Hypertension treatment, n (%) 153 (55.64 %) 275 48 (46.6 %) 103 0.12
Cardiovascular disease, n (%) 67 (24.63 %) 275 20 (19.4 %) 103 0.31
Description of the full CRESCENDO cohort and sample taken for this study after removal of participants with unusable data. Were assessed at baseline: alcohol consumption,
NART (National Adult Reading Test), and smoking status. At 10 y, biological data (except BMI). At 12 y, BMI, and cardiovascular factors. Data are expressed asmean and standard
deviation except as noted. Number of available observations of each variable is displayed. Differences between the initial cohort and our sample is investigated through c2 test
or 2 sample t-test. p-values in bold highlight a significant difference between the groups according to a 0.05 threshold.
Key: BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; MAP, mean arterial pressure; MMSE, mini-mental state examination.
J. Deverdun et al. / Neurobiology of Aging 46 (2016) 49e5754account this variable as confounding factor in CBF-related studies.
Men have a lower life expectancy. and it has been shown that lower
CBF is associated to an increase risk of all-cause mortality (Sabayan
et al., 2013).
As sex, aging effect on CBF is well-documented both using
arterial spin labeling and positron emission tomography (Chen
et al., 2011; Martin et al., 1991). Nevertheless, we were not able to
see any association between age and CBF in our cohort. This null
finding might be due to the age homogeneity of our cohort, pre-
venting the observation of any statistically significant age-
dependent effect.4.3. Diabetes and glycemia
Diabetes has been shown to reduce cerebrovascular reactivity
(Dandona et al., 1978; Fülesdi et al., 1997). The absence of associa-
tion between type 2 diabetes and CBF values might be due here to a
power, with only 13 cases of type 2 diabetes. Glycemia levels and
their evolution, although not significant after Bonferroni’s correc-
tion, show a negative trend with CBF. Low levels of glycemia have
been associated to an increased CBF (Arbeláez et al., 2013), and
reciprocally hyperglycemia is related to a decreased CBF (Duckrow,1995). High levels of glycemia may increase arterial stiffness
through alteration of the arterial wall (Rubin et al., 2012). Moreover,
increased arterial stiffness is known to be associated with increased
cerebrovascular resistance and reduced CBF (Kielstein et al., 2006;
Lipsitz et al., 2005; Robertson et al., 2010).
Nevertheless, as explained in the methodological discussion in
the following, excluded participants because of ASL quantification
issues had significantly higher glycemia levels. This, of course,
induces a bias in our sampling because it prevents us from
including most of the high glycemia participants and may explain
the weak correlation we observed.4.4. Other variables
In previous studies, decreased CBF were observed with
increasing BMI (Willeumier et al., 2011), chronic alcohol con-
sumption (Christie et al., 2008), and cigarette smoking (Kubota
et al., 1983). We were not able to see any correlation between
those factor and CBF. The explanation is that, like age, their range of
values in our sample is narrow. The 2-year gap between the last
assessment of these biological data and the MRI examination
should also be kept in mind and is a limitation on our conclusions.
Fig. 3. Impact of inversion time (TI) on number of removed repetitions. Pertinence of our quality control criteria is investigated. In (A), the number of repetitions that have been
removed according to our criteria is displayed for 1 subject for multiple inversion time. The dots correspond to the real value, the blue curve is a second degree polynomial fit on
the data, and finally, the red arrow highlight the optimal inversion time identified on the bolus arrival time map (1555 ms). The value measured on the map is concordant with the
minimum of the curve. (B) This shows the average number of removed repetitions for all participants according to the absolute distance of the inversion time to the optimal one.
The center red line is the average, the top and bottom lines show the standard deviation. When the distance to the optimal inversion time increases, the number of repetitions that
have to be removed is increased. (C) This shows the optimal inversion time (in ms) identified by drawing regions of interest on bolus arrival time map (“measured TI”) compared
with the inversion time with the less number of removed repetition for each participants (“estimated TI”). The 2 values are very close. (For interpretation of the references to color in
this figure legend, the reader is referred to the Web version of this article.)
J. Deverdun et al. / Neurobiology of Aging 46 (2016) 49e57 55Finally, no clear association between self-reported cardiovas-
cular events and CBF was found. We nevertheless have to keep in
mind that our participants’ recruitment in itself selects a healthypopulation. Indeed, the prevalence of cardiovascular events in our
group is far below the average for participants of this age (American
Heart Association, Inc, 2013).
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The main strengths of this study include (1) a large cohort; (2) a
long follow-up time of 12 years; and (3) availability of extensive
data on cardiovascular risks factors. Our conclusions have never-
theless limitations due to various factors.
The first limitation comes from the cohort selection of “highly”
healthy older adults, which prevents generalization of our findings
to the general population of older adults. Indeed, we know that
there is a far higher prevalence of CVDs and risk factors in this age
range in the general population.
Moreover, note that we only had access to late-life vascular risk
factors information. Yet, it has been shown that mid-life risk factors
are more influential (Roberts et al., 2015).
For some factors such as diabetic status or particular CVDs, the
lack of statistical power in our cohort could explain the absence of
correlation with CBF.
Finally, we have to remember that we only have 1 measure of
the CBF at 12 years. Although we observed associations between
specific factors and the CBF values, at least 1 additional perfusion
acquisitionwould be required to assess their relation to CBF change.
The last crucial methodological point concerns the exclusion of
large number of participants due to CBF quantification issues, and
its influence on our conclusions.
Currently, very few studies have been performed on cohorts of
older adults (mean age >80-year old) using arterial spin labeling.
In our case, this acquisition was the last sequence of a long pro-
tocol, and after more than 45 minutes, participants can be tired
and exhibit increased motion. Moreover, we were constrained by
coherence across the study to use a single inversion time for all
participants, which could be inadequate due to arterial transit
time variations. These factors, together with labeling in-
homogeneity or the presence of surgical clips, are known to alter
the quality of CBF quantitative measurement (Alsop et al., 2014).
Thus, a particular care had to be taken, through the use of a strict
objective criterium described in the Materials and methods Sec-
tion, to prevent the use of corrupted data. As a consequence of this
strict threshold for inclusion, an important number of participants
had to be removed.
Among the excluded participants no sign of major motion or
labeling inhomogeneity was identified. In addition, no participants
had surgical clip that could explain those errors. Our further anal-
ysis suggests that inappropriate inversion time is the main factor
for the large exclusion number.
Optimal inversion time is closely associated to medical history
(Campbell and Beaulieu, 2006) and can strongly vary in older
adults. As shown on Fig. 3B from our test data on younger adults,
when the sequence inversion time varies, the number of removed
(>50% negative values) repetitions goes through a minimum. Let us
define the optimal inversion time as the one leading to the lowest
number of removed repetitions. So defined, it can be shown in our
young adults group (Fig. 3A and C) to coincide with the real one, as
obtained from an independent 3D multi-inversion time ASL pro-
tocol. Taken together, these results support the hypothesis that the
incorrect inversion time is the main factor for repetitions removal.
This creates a specific problem for ASL studies involving older
adults, and our study is to our knowledge the first one to be based
on a large cohort of such participants. Indeed, for younger adults,
transit time do not exhibit the same variability (Campbell and
Beaulieu, 2006), which explains that the application of a rigorous
quality criterium is not explicitly mentioned. The exceptionally
large number of excluded patients in our case results from the
nature of our cohort that imposes this methodological rigor.
What about the bias in our conclusions induced by this selection
criterium?Based on comparison between excluded and included partici-
pants, only BMI, glycemia, age, and sex appear indeed to be
significantly different. Note that among these factors, BMI, age and
sex have been shown to modify the arterial transit time, in agree-
ment with our hypothesis (Liu et al., 2011; MacIntosh et al., 2014).
Glycemia has not been investigated in that respect.
But do we bias the measured CBF values themselves? It is hard to
speculate on the excluded population CBF values. We can only be
assured that the datawe select are the only usable part of our whole
ASL data set and that the extracted CBF values are coherent. The
criteriumwe applied in selecting our exclusion threshold was based
on the coherence of the CBF values: among participants for which
less than 20% of repetitions have been excluded there is no associa-
tion (Pearson correlation,p> 0.05) between thenumberof repetition
excluded and themeasured CBF values). Such artefactual correlation
exists for excluded data (Pearson correlation, p < 0.05), only due to
the fact that when negative artefactual values are present (whichwe
eliminate), positive artefactual values are also present, which
contribute to a global artefactual increase in the CBFmeasure. For the
excluded participants, we thus just cannot access the CBF values and
cannot rule out thepossibility that the corresponding CBF, if correctly
measured couldmodify our results. We only have no hints regarding
the possible origin of such a bias. Other studies dedicated to large
cohorts of olderadults are obviously necessary, usingmulti-inversion
time ASL or other perfusion techniques, to further investigate the
association between cardiovascular risks and cerebral blood flow.5. Conclusion
The main strengths of this study are the availability of CBF map-
ping for an unusually large number of older adults, along with soci-
odemographic and cardiovascular factors across a 12-year period.
Our findings suggest that evolution of MAP is the most mean-
ingful factor to take into account in older adults to reduce risks
related to low CBF. In addition, our work highlighted the impor-
tance of quality check with this kind of population.
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